Pancreatic cancer test developer Bluestar Genomics has raised $70m from investors including Pathology Asia Holdings.
Medical diagnostics group Pathology Asia Holdings participated in a $70m series C round for US-based cancer diagnostics technology developer Bluestar Genomics on Wednesday.
The round was led by Mattias Westman, founding partner of asset management firm Prosperity Capital Management, while an undisclosed venture capital fund and an unnamed asset manager also took part. Vahoca was financial adviser for Bluestar on the deal.
Bluestar is exploring cancer screening products focusing on the genetic material of cells, otherwise known as the epigenome.…
